SME Times is powered by   
Search News
Just in:   • White paper on black money tabled in LS  • Rupee slips to a record low of 55 against a dollar  • Myanmar economy set to boom: Report  • IT industry seeks clarity on software exports: Murthy  • Sensex closes flat on weak rupee 
Last updated: 13 Feb, 2012  

Jubilant and Endo Pharma Achieve an Early Stage Milestone

PR Newswire | 09 Feb, 2012
Jubilant and Endo Pharmaceuticals Announce Successful Delivery of Early Milestones in Collaborative Discovery Program

BANGALORE, India: Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford, Pa., USA-based Endo Pharmaceuticals that has nominated a candidate into full development. The novel molecule, targeting cancer, is anticipated to go into clinical trials by late 2012. Jubilant and Endo will continue the collaboration in the development phase as well.  

The multi-target collaboration that began three years ago focuses on Best in Class differentiated therapies to address the unmet needs of cancer patients worldwide.  The collaboration has since delivered multiple milestones across the discovery phase.  Endo will pursue development and commercialization of the compound, while Jubilant becomes eligible to receive development milestones.

"We are very pleased and elated with this successful outcome, which is a result of the excellent collaboration between the scientists at Endo and Jubilant," said Sri Mosur, CEO & President, Global Drug Discovery and Development, Jubilant. "Jubilant has pioneered from India, a business model based on shared risk that enables it to demonstrate the differentiated and novel outcomes that Jubilant scientists are able to deliver through accelerated and affordable innovation to its many collaborators."

Sandeep Gupta, Endo Pharmaceuticals, Senior Vice President, Discovery & Early Development , said, "I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled nomination of a development candidate ahead of schedule in less than two years since inception of this program. Initiation of this development program further validates Endo's unique collabrative drug discovery approach which aims to address unmet medical needs and improve patient outcomes."  

About Us

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.

http://www.jubilantbiosys.com

Contact For Business Queries

Narendra Kumar
+91(0)80-6662840
narendra_kumar@jubilantbiosys.com

SOURCE Jubilant Biosys Ltd and Endo Pharmaceuticals

 
Print the Page Add to Favorite
 

Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

   Top Stories
» Rupee slips to a record low of 55 against a dollar
» Experts welcome SIDBI fund for service sector start-up SMEs
» Forex reserves drop by USD 1.37 billion
» Amid global woes, exporters seek more support
» Rupee crisis a great concern: Pranab
 
  Commented Stories
» Credit rating can help SMEs in more ways than one(20)
» Exporters need push, not pull(10)
» SME Conclave – awareness on SME stock exchange(6)
» Share of MSME sector in GDP to touch 10 pc: Ashok Chawla(6)
» Yamaha records domestic sales growth of 53 pc(3)
  Customs Exchange Rates
Currency Import Export
US Dollar
53.10
52.25
UK Pound
86.00
84.15
Euro
70.35
68.70
Japanese Yen 65.50 63.85
As on 21 May, 2012
  Daily Poll
Do you think RBI's deregulation of export credit interest rate in foreign currency will affect exporters?
 Yes
 No
 Can't say
 
 
 
 
About Us  |  Contact Us  |  Feedback |  Success Stories |  Tradeindia in News  |  Get Listed | 
Sitemap  |  Terms of Use |  Useful Links |  Trade Bodies